Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		×
			NIOSH
			NIOSH

				All CDC
				Submit


The National Institute for Occupational Safety and Health (NIOSH)





Current Intelligence Bulletin 6: Hexamethyl -phosphoric Triamide (HMPA)						Print
																Related Pages
										October 24, 1975
DHHS (NIOSH) Publication Number 78-127
Department of Health, Education, and Welfare
Public Health Service
Center for Disease Control
National Institute for Occupational Safety and Health
5600 Fishers Lane
Rockville, Maryland 20852
Dear Colleague:
The enclosed background material on *Hexamethylphosphoric Triamide* has been prepared by the Office of Occupational Health Surveillance and Biometrics, National Institute for Occupational Safety and Health to alert members of the occupational health community to new infomation on a potential occupational hazard.
Your comments and suggestions for changes to future reports are solicited.
Sincerely yours,*[signature]*
J. William Lloyd, Sc.D., Director
Office of Occupational Health
Surveillance and Biometrics
Summary
The National Institute for Occupational Safety and Health (NIOSH) has received a report from an American producer of hexamethylphosphoric triamide (HMPA), a synthetic organic chemical, indicating that malignant tumors have been produced in laboratory animals by exposure to HMPA.
In light of the potential risk of human exposure to this chemical in the work environment, the National Institute for Occupational Safety and Health is advising the occupational health community of these findings.
Introduction
The E.I. du Pont de Nemours and Company (Du Pont) reported to the National Institute for Occupational Safety and Health in a letter dated September 24, 1975, that nasal tumors (squamous cell carcinoma) have been observed in rats exposed to hexamethylphosphoric triamide. NIOSH has also been advised that Du Pont has notified its customers and employees of these findings.
Background
HMPA is a colorless liquid with a density of 1.03 g/ml and a boiling point of 232°C. Synonyms for hexamethylphosphoric triamide include ENT 50882, hempa, hexametapol, hexamethylphosphamide, hexamethylphosphoramide, hexamethylphosphoric acid triamide, hexamethylphosphorotriamide, hexamethylphosphotriamide, HMPA, HMPT, HPT, phosphoric tris (dimethyamide), phosphoryl hexamethyltriamide, tris (dimethylamino) phosphine oxide, and tris (dimethylamino) phosphorous oxide. 1
Hexamethylphosphoric triamide is a material possessing unique solvent properties and is widely used as a solvent, in small quantities, in organic and organo-metallic reactions in laboratories. 2,3 This is the major source of occupational exposure to HMPA in the United States.
Du Pont, the major manufacturer of hexamethylphosphoric triamide in the United States, periodically produces HMPA at its Chambers Works, Deepwater, New Jersey. Other producers of HMPA in the United States include Chemical Samples Company and Fike Chemical Company. None of Du Pont’s HMPA is marketed; all is used internally at its Spruance Plant in Richmond, Virginia, as a processing solvent in the production of  Kevlar* aramid fiber. Du Pont reports that Kevlar contains less than 1 ppm (w/w) of the HMPA which is so firmly held by the fiber that Du Pont believes there is no hazard to customers or employees handling the final fiber product.
Hexamethylphosphoric triamide had been manufactured and distributed in the past by Dow Chemical Company ( as DORCOL) and Eastman Chemical Products, Inc. ( as Inhibitor HPT). Both firms have advised NIOSH that they discontinued these products several years ago. 4 HMPA has been evaluated for use as an ultraviolet light inhibitor in polyvinyl chloride formulations, as an additive for antistatic effects, as a flame retardant, and as a de-icing additive for jet fuels.4-6
Hexamethylphosphoric triamide has also been extensively investigated as an insect chemosterilant.7,8
Toxicity
Human
There are no data available on the toxic effects of hexamethylphosphoric triamide in humans.
Animal
HMPA is known to have a variety of toxic effects on laboratory animals. Acute toxic effects seen in rats fed HMPA include kidney disease, severe bronchiectasis and bronchopneumonia with squamous metaplasia and fibrosis in lungs.9,10 In rabbits, repeated application of HMPA to the skin caused dose related weight loss, altered gastrointestinal function and apparent nervous-system dysfunction. ll Testicular atrophy and aspermia have been observed in rats following oral treatment with HMPA.9,12 Oral treatment with HMPA has also been highly inhibitory to testicular development in cockerels.13
HMPA is known to produce mutagenic effects in fruit flies (Drosophila melanogaster).14 However, studies of the effects of HMPA on human15 and mice chromosomes 16 showed no greater frequency of HMPA induced chromosomal aberrations when compared with controls.
Preliminary results of an inhalation toxicity study of HMPA, recently released by Du Pont, show nasal tumors in rats exposed daily to 400 and 4,000 parts per billion (ppb) HMPA after 8 months of exposure. In some cases, the tumors originating from the epithelial lining of the nasal turbinate bones filled the nasal cavity and penetrated into the brain. No nasal tumors were reported among rats exposed to 50 ppb HMPA and controls.
Prior to the Du Pont observations, the only other known report of tumors associated with exposure to HMPA was a long-term feeding study by Kimbrough. While lung tumors were observed, the results of this study were inconclusive because the tumor incidence among HMPA exposed rats was not greater than among the control rats. 17
Occupational Exposure
It is estimated that 5,000 people are occupationally exposed to hexamethylphosphoric triamide. More than 90 percent of these exposures are in research laboratories.
Permissible Occupational Exposure
There is no current Occupational Safety and Health Administration, Department of Labor standard for hexamethylphosphoric triamide exposure.
Producers and Distributors
The following is a list of the major producers and distributors of hexamethylphosphoric triamide:
Producers and Distributors
Producers
LocationE.I. du Pont de Nemours & Co., Inc.
Deepwater, NJChemical Samples Company
Columbus, OHFike Chemical Company
Nitro, WV**Distributors****
**Location**Aldrich Chemical Company
Milwaukee, WSJ.T. Baker Chemical Company
Phillipsburg, NJBodman Chemicals
Aston Township, PAChemical Samples Company
Columbus, OHEastman Organic Chemicals
Rochester, NYE.M. Laboratories, Inc.
Elmsford, NYFike Chemical Company
Nitro, WVFisher Scientific Company
Pittsburgh, PAGuardian Chemical Corporation
Hauppauge, NYMCB Manufacturing Chemists
Cincinnati, OHOrgmet
E. Hampstead, NHPeninsular Chemical Research, Inc.
Gainesville, FLPolyscience, Inc.
Warrington, PA*[Source:] Personal communications with representatives of chemical manufacturers, October, 1975*
Notes
* Kevlar is a registered trademark of the Du Pont Company [return to main text]
** Includes domestic and imported HMPA [return to table]
Bibliography
CHEMLINE, National Library of Medicine, Bethesda, Maryland, October, 1975
Fieser, M. and Fieser, L.F.: for Organic Synthesis, John Wiley and Sons, Inc., New York, 4:244, 1974; 3:149, 1972; 2:208, 1969; 1:430, 1967
Chemical Abstracts, Chemical Substances Index, Chemical Abstracts Service, Columbus, Ohio, Vol. 81, 1974
Personal communication with representatives of Dow Chemical Company, Midland, Michigan, and Eastman Chemical Products, Inc., Kingsport, Tennessee
Eastman Technical Data Sheet No. X-203, Eastman Chemical Products, Inc., Kingsport, Tennessee
The Merck Index, 8th Ed., Merck and Company, Inc., Rahway, New Jersey, p. 528, 1968
Bull, D.L. and Borkovec, A.B.: of Carbon-14-Labeled Hempa by Adult Boll Weevils, Arch Environ Contam Toxicol, 1(2):148-58, 1973
Landa, V.: of Chemosterilants in the Reproductive Organs and Tissues of Insects, Proc, Int Cong Entomol, 13th, 3:423-24, 1972
Kimbrough, R.D. and Gaines, T.B.: of Hexamethylphosphoramide in Rats, Nature, 211:146-47, 1966
Kimbrough, R.D. and Sedlak, V.A.: Morphology in Rats Treated with Hexamethylphosphoramide, Toxicol Appl Pharmacol, 12(l):60-7, 1968
Shott, L.D., Borkovec, A.B., and Knapp, W.A., Jr.: of Hexamethylphosphoric Triamide in Rats and Rabbits, Toxicol Appl Pharmacol, 18(13):499-506, 1971
Jackson, H., Jones, A. R., and Cooper, E.R.A.: of Hexamethylphosphoramide on Rat Spermatogenesis and Fertility, J Repro Fertil, 20:263-69, 1969
Sherman, M. and Herrick, R.B.: Toxicity of Five Insect Chemosterilants, Hemel, Hempa, Tepa, Metepa, and Methotrexate, for Cockerels, Toxicol Appl Pharmacol, 16:100-07, 1970
Benes, V. and Sram, R.J.: Activity of Some Pesticides in Drosophila Melanogaster, Indus Med Surg, 38(12):442-44, 1969
Chang, T.H. and Klassen, W.: Effects of Tretamine, Tepa, Apholate, and Their Structural Analogs on Chromosomes in Vitro, Chromasoma, 24(3):314-23, 1968
Manna, G.K. and Das, P.K.: of two Chemosterilants Apholate and Hempa on the Bone-Marrow Chromosomes of Mice, Can J Genet Cytol, 15(3):451-59, 1973
Kimbrough, R.D. and Gaines, T.B.: Chronic Toxicity of Hexamethylphosphoramide in rats, Bull Environ Contam and Toxicol, 10(4)225-26, 1973
							
					
							Last Reviewed:  June 6, 2014						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Error processing SSI file  Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue